Related Experiment Videos
Comparative bioavailability of Silipide, a new flavanolignan complex, in rats
P Morazzoni1, M J Magistretti, C Giachetti
1Inverni della Beffa Research and Development Laboratories, Milan, Italy.
European Journal of Drug Metabolism and Pharmacokinetics
|January 1, 1992
Summary
Silipide (silybin-phosphatidylcholine complex) significantly enhances silybin bioavailability compared to silybin alone. This improved absorption is key for effective silybin delivery and therapeutic potential.
Area of Science:
- Pharmacology
- Drug Delivery Systems
- Natural Product Chemistry
Background:
- Silybin, a major component of silymarin, exhibits poor oral bioavailability.
- Developing effective delivery systems for silybin is crucial for its therapeutic applications.
Purpose of the Study:
- To compare the pharmacokinetics of Silipide (IdB 1016), a silybin-phosphatidylcholine complex, with silybin.
- To evaluate the impact of the phosphatidylcholine complex on silybin absorption and excretion.
Main Methods:
- Rats were administered a single oral dose of Silipide or silybin (200 mg/kg).
- Plasma silybin levels (unconjugated and total) were measured.
- Biliary and urinary excretion of silybin were quantified.
Main Results:
- Silipide administration resulted in significantly higher plasma silybin levels (mean peak total: 74.23 µg/mL) compared to undetectable levels after silybin administration.
- Approximately 94% of plasma silybin was in conjugated form after Silipide administration.
- Cumulative excretion of Silipide was 3.73% (biliary) and 3.26% (urinary), significantly higher than silybin (0.001% biliary, 0.032% urinary).
Conclusions:
- Silipide demonstrates superior oral bioavailability compared to silybin.
- The phosphatidylcholine complexation significantly enhances gastrointestinal absorption of silybin.
- Silipide represents a promising formulation for improving silybin's therapeutic efficacy.